ICCC
Price
$10.06
Change
-$0.03 (-0.30%)
Updated
Aug 21 closing price
Capitalization
91.37M
81 days until earnings call
Intraday BUY SELL Signals
NKTX
Price
$2.66
Change
+$0.19 (+7.69%)
Updated
Aug 21 closing price
Capitalization
190.52M
80 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ICCC vs NKTX

ICCC vs NKTX Comparison Chart in %
View a ticker or compare two or three
VS
ICCC vs. NKTX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICCC is a Hold and NKTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (ICCC: $10.06 vs. NKTX: $2.66)
Brand notoriety: ICCC and NKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ICCC: 27% vs. NKTX: 171%
Market capitalization -- ICCC: $91.37M vs. NKTX: $190.52M
ICCC [@Biotechnology] is valued at $91.37M. NKTX’s [@Biotechnology] market capitalization is $190.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ICCC’s FA Score shows that 1 FA rating(s) are green whileNKTX’s FA Score has 1 green FA rating(s).

  • ICCC’s FA Score: 1 green, 4 red.
  • NKTX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ICCC and NKTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ICCC’s TA Score shows that 4 TA indicator(s) are bullish while NKTX’s TA Score has 5 bullish TA indicator(s).

  • ICCC’s TA Score: 4 bullish, 6 bearish.
  • NKTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NKTX is a better buy in the short-term than ICCC.

Price Growth

ICCC (@Biotechnology) experienced а +0.10% price change this week, while NKTX (@Biotechnology) price change was +14.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

ICCC is expected to report earnings on Nov 12, 2026.

NKTX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NKTX($191M) has a higher market cap than ICCC($91.4M). ICCC YTD gains are higher at: 63.577 vs. NKTX (43.784). ICCC has higher annual earnings (EBITDA): 2.48M vs. NKTX (-107.08M). NKTX has more cash in the bank: 230M vs. ICCC (6.81M). ICCC has less debt than NKTX: ICCC (12.8M) vs NKTX (75M). ICCC has higher revenues than NKTX: ICCC (29.9M) vs NKTX (0).
ICCCNKTXICCC / NKTX
Capitalization91.4M191M48%
EBITDA2.48M-107.08M-2%
Gain YTD63.57743.784145%
P/E Ratio143.71N/A-
Revenue29.9M0-
Total Cash6.81M230M3%
Total Debt12.8M75M17%
FUNDAMENTALS RATINGS
ICCC vs NKTX: Fundamental Ratings
ICCC
NKTX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9098
PRICE GROWTH RATING
1..100
4349
P/E GROWTH RATING
1..100
3100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NKTX's Valuation (8) in the null industry is significantly better than the same rating for ICCC (99) in the Medical Specialties industry. This means that NKTX’s stock grew significantly faster than ICCC’s over the last 12 months.

NKTX's Profit vs Risk Rating (100) in the null industry is in the same range as ICCC (100) in the Medical Specialties industry. This means that NKTX’s stock grew similarly to ICCC’s over the last 12 months.

ICCC's SMR Rating (90) in the Medical Specialties industry is in the same range as NKTX (98) in the null industry. This means that ICCC’s stock grew similarly to NKTX’s over the last 12 months.

ICCC's Price Growth Rating (43) in the Medical Specialties industry is in the same range as NKTX (49) in the null industry. This means that ICCC’s stock grew similarly to NKTX’s over the last 12 months.

ICCC's P/E Growth Rating (3) in the Medical Specialties industry is significantly better than the same rating for NKTX (100) in the null industry. This means that ICCC’s stock grew significantly faster than NKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ICCCNKTX
RSI
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
76%
MACD
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 17 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 26 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
67%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ICCC
Daily Signal:
Gain/Loss:
NKTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OCMGX37.760.97
+2.64%
OCM Gold Investor
GCIGX21.880.25
+1.16%
Gabelli International Growth C
GCIUX21.040.23
+1.11%
Goldman Sachs Intl Eq Insghts R6
JMCVX17.25N/A
N/A
Janus Henderson Mid Cap Value T
TOLSX15.95-0.18
-1.12%
DWS RREEF Global Infrastructure S

NKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with EDIT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
+7.69%
EDIT - NKTX
52%
Loosely correlated
+5.78%
RXRX - NKTX
49%
Loosely correlated
+4.79%
PRME - NKTX
49%
Loosely correlated
+4.63%
VIR - NKTX
47%
Loosely correlated
+6.19%
RCKT - NKTX
47%
Loosely correlated
+0.86%
More